Publications



 References using the ESTRAMETTM 2/16 EIA kits of IMMUNA CARE for
2- and 16a-Hydroxyestrone in Urine and Serum  (to 02/20/07)

  1. McCann SE, Wactawski-Wende J, Kufel K, Olson J, Ovando B, Kadlubar SN, Davis W, Carter L, Muti P, Shields PG, Freudenheim JG.  (2007).  Changes in 2-hydroxyestrone and 16{alpha}-hydroxyestrone metabolism with flaxseed consumption: modification by COMT and CYP1B1 genotype.  Cancer Epidemiol Biomarkers and Prev 16: 256-262.
  2. Lippert TH, Adlercreutz H, Berger MR, Seeger H, Mueck AO. (2007).  Urinary phytoestrogen excretion of  rats bearing methylnitrosourea-induced mammary carcinoma in response to treatment with 2-methoxyestradiol.  J Steroid Biochem Mol Biol  103: 158-162.  
  3. Cutolo M, Capellino S, Sulli A, Serioli B, Secchi ME, Villaggio B, Straub RH. (2006).  Estrogen and autoimmune diseases.  Ann NY Acad Sci  1089: 538-547.

  4. Wood CE, Register TC, Cline JM. (2006).  Soy isoflavonoid effects on endogenous estrogen metabolism in postmenopausal female monkeys.  Oct 9; [Epub ahead of print].
     
  5. Klug TL, Bageman E, Ingvar C, Rose C, Jernstrom H.  (2006).  Moderate coffee consumption improves the estrogen metabolite profile in adjuvant treated breast cancer patients: a pilot study comparing pre- and post-operative levels.  Mol Genet Metab 89:381-389. 
  6. Sowers MR, Wilson AL, Kardia SR, Chu J, McConnell DS.  (2006).  Cyp1A1 and cyp1B1 polymorphisms and their association with estradiol and estrogen metabolites in women who are premenopausal and perimenopausal.   Am J Med  19:(S9 Suppl 1) S44-51.
  7. Sowers MR, McConnell D, Jannausch M, Buyuktur AG, Hochberg M, Jannadar DA. (2006).  Estradiol and its metabolites and their association with knee arthritis.   Arthritis Rheum 54:2481-2487.
  8. Greenlee H, Chen Y, Kabat GC, Wang Q, Kibriya MG, Gurvich I, Sepkovic DW, Bradlow HL, Senie RT,  Santella RM, Ahsan H.  (2006).  Variants in estrogen metabolism and biosynthesis genes and urinary estrogen metabolites in women with a family history of breast cancer.  Breast Cancer Res Treatment Jul 19; [Epub ahead of print].
  9. Chan EK, Sepkovic DW, Yoo Bowne HJ, Yu GP, Schantz, SP.  (2006).  A hormonal association between estrogen metabolism and proliferative thyroid disease.  Otolaryngol head neck surg 134:893-900.
  10. Sowers MR, Crawford S, McConnell DS, Randolph JF Jr, Gold EB, Wilkin MK, Lasley B.  (2006).  Selected diet and lifestyle factors are associated with estrogen metabolites in multiracial/ethnic population of women.  J Nutr 136:1588-1595.
  11. Naik R, Nixon S, Lopes A, Godfrey K, Hatem MH, Monaghan JM. (2006).  A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia. Int J Gynecol Cancer 16:786-790.
  12. Wu WH, Kang YP, Wang NH, Jou HJ, Wang TA. (2006). Sesame ingestion affects sex hormones, antioxidant status, and blood lipids in postmenopausal women. J Nutr 136:1270-1275.
  13. Modugno F, Kip KE, Cochrane B, Kuller L, Klug TL, Rohan TE, Chlebowski RT, Lasser N, Stefanick ML. (2006).  Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer.
    Int J Cancer 118:1292-1301.
  14. Kabat GC, O'leary ES, Gammon MD, Sepkovic DW, Teitelbaum SL, Britton JA, Terry MB, Neugut AI, Bradlow HL. (2006).  Estrogen Metabolism and Breast Cancer.  Epidemiology  17:80-88.
  15. Masi CM, Hawkley LC, Berry JD, Cacioppo JT . (2005).  ESTROGEN METABOLITES AND SYSTOLIC BLOOD PRESSURE IN A POPULATION-BASED SAMPLE OF POSTMENOPAUSAL WOMEN.   J Clin Endocrinol Metab. 91:1015-20. Epub 2005 Dec 29.
  16. Teas, J, Cunningham JE, Fowke JH, Nitcheva D, Kanwat CP, Boulware RJ, Sepkovic DW, Hurley TG, Herbert JR. (2005). Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina.  Cancer Detect Prev. 29:494-500.
  17. Wu WH, Lu SC, Wang TF, Jou HJ, Wang TA. (2005). .Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women.  Eur J Clin Nutr  60:386-92. 
  18.  Lukaczer D, Darland G, Tripp M, Liska D, Lerman RH, Schiltz B, Bland JS.(2005). Clinical effects of a proprietary combination isoflavone nutritional supplement in menopausal women: a pilot trial. Altern Ther Health Med 11:60-65.
  19. Wellejus A, Olsen A, Tjonneland A, Thomsen BL, Overad K, Loft S. (2005).  Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study.  Cancer Epidemiol Biomarkers Prev  9: 2137-2142.
  20. Bradlow HL, Jernstrom H, Sepkovic DW, Klug TL. Narod SA. (2005). Comparison of plasma and urinary levels of 2-hydroxyestrogens and 16alpha-hydroxestrogen metabolites.  Mol Genet Metab 87:135-46. Epub 2005 Sep 13.
  21. Reed GA, Peterson KS, Smith HJ, Gray JC, Sullivan DK, Mayo MS, Crowell JA, Hurwitz A. (2005).  A phase I study of indole-3-carbinol in women: tolerability and effects.  Cancer Epidemiol Biomarkers  Prev 8:1953-1960.
  22. Wu WH, Liu LY, CHung CJ, Jou HJ, Wang TA. (2005). Estrogenic effect of yam ingestion in healthy postmenopausal women.  J Am Coll Nutr. 4:235-43.
  23. Campbell KC, Westerlind KC, Harber VJ, Friedenreich CM, Courneya KS. (2005).  Associations between aerobic fitness and estrogen metabolites in premenopausal women.  Med Sci Sports Exerc  37:585-92.
  24. Bentz AT, Schneider CM, Westerlind KC. (2005).   The relationship between physical activity and 2-hydroxyestrone, 16alpha-hydroxyestrone, and the 2/16 ratio in premenopausal women (United States).
    Cancer Causes Control  16 :455-61.
  25. Lurie G, Maskarinec G, Kaaks R, Stanczyk FZ, Le Marchand L. (2005).  Association of genetic polymorphisms  with serum estrogens measured multiple times during a 2-year period in premenopausal women.  Cancer Epidemiol Biomarkers Prev 14:1521-7.
  26. Nettleton JA, Greany KA, Thomas W, Wangen KE, Adlercreutz H, Kurzer MS. (2005).  The effect of soy consumption on the urinary 2:16-hydroxyestrone ratio in postmenopausal women depends on equol production status but is not influenced by probiotic consumption. J Nutr 135:603-608.
  27. Napoli N, Donepudi S, Sheikh S, Rini GB, Armamento-Villareal R. (2005).  Increased 2-hydroxylation of Estrogen in Women with Family History of Osteoporosis.  J Clin Endocrinol Metab  90:2035-41.
  28. Napoli N, Villareal DT, Mumm S, Halstead L, Sheikh S, Cagaanan M, Rini GB,Armamento-Villareal R. (2005). Effect of CYP1A1 Gene Polymorphisms on Estrogen Metabolism and Bone Density.  J Bone Miner Res  20:232-239.
  29. Falk RT, Fears TR, Xu X, Hoover RN, Pike MC, Wu AH, Nomura AM, Kolonel LN, West DW, Sepkovic DW, Bradlow HL, Ziegler RG. (2005).   Urinary Estrogen Metabolites and Their Ratio among Asian American Women.   Cancer Epidemiol Biomarkers Prev  14:221-226.
  30. Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF. (2004). Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer.  Nutr Cancer 50:161-167.
  31. Armamento-Villareal RC, Napoli N, Klug T, Civitelli R. (2004). The oxidative metabolism of estrogen modulates response to ERT/HRT in postmenopausal women.  Bone  35:682-688.
  32. Matthews CE, Fowke JH, Dai Q, Leon Bradlow H, Jin F, Shu XO, Gao YT, Longcope C, Hebert JR, Zheng W.  (2004).  Physical activity, body size, and estrogen metabolism in women.   Cancer Causes Control  15:473-481.
  33. Soliman A, Vulimiri S, Kleiner H, Shen J, Eissa S, Morad M, Taha H, Lukmanji F, Li D, Johnston D, Lo HH, Lau S, Digiovanni J, Bondy M. (2004).  High levels of oxidative DNA damage in lymphocyte DNA of premenopausal breast cancer patients from Egypt.  Int J Environ Health Res . 14:121-134.
  34. Atkinson C, Lampe JW, Tworoger SS, Ulrich CM, Bowen D, Irwin ML, Schwartz RS, Rajan BK, Yasui Y, Potter JD, McTiernan A.  (2004). Effects of a moderate intensity exercise intervention on estrogen metabolism in postmenopausal women.  Cancer Epidemiol Biomarkers Prev  13:868-74.
  35. Frankenfeld CL, McTiernan A, Tworoger SS, Atkinson C, Thomas WK, Stanczyk FZ, Marcovina SM, Weigle DS, Weiss NS, Holt VL, Schwartz SM, Lampe JW. (2004).  Serum steroid hormones, sex hormone-binding globulin concentrations, and urinary hydroxylated estrogen metabolites in post-menopausal women in relation to daidzein-metabolizing phenotypes.   J Steroid Biochem Mol Biol  88 :399-408
  36. Weidler C, H@rle P, Schedel J, Schmidt M, Sch`lmerich J, and Straub RH. (2004). Patients with Rheumatoid Arthritis and Systemic Lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens. J Rheumatology  31: 89-94. 
  37. Cutolo M. (2004).  Editorial :  Estrogen metabolites: increasing evidence for their role in rheumatoid arthritis and systemic lupus erythematosus. J Rheumatology  31:419-421.
  38. Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, Stanczyk FZ, McTiernan A. (2004).  Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev . 13:94-101.
  39. Brooks JD, Ward WE, Lewis JE, Hilditch J, Nickell L, Wong E, Thompson LU. (2004).  Supplementation with flaxseed alters estrogen metabolism in postmenopausal women to a greater extent than does supplementation with an equal amount of soy.  Am J Clin Nutr   79:318-25. 
  40. Mueck AO, Seeger H, Wallwiener D. (2004).  Endogenous metabolism during treatment with oral contraceptives.  Int J Clin Pharmacol Ther 42: 160-164.
  41. Mueck AO, Seeger H, Lippert TH. (2003). Estrogen-dependent Neoplasia - What is the significance of estradiol metabolites : Zentralbl Gynakol  125:458-66.
  42. Auborn KJ, Qi M, Yan XJ, Teichberg S, Chen D, Madaio MP, Chiorazzi N. (2003). Lifespan is prolonged in autoimmune-prone (NZB/NZW) F1 mice fed a diet supplemented with indole-3-carbinol. J Nutr 133:3610-3.
  43. Atkinson C, Skor HE, Dawn Fitzgibbons E, Scholes D, Chen C, Wahala K, Schwartz SM, Lampe JW. (2003). Urinary equol excretion in relation to 2-hydroxyestrone and 16alpha-hydroxyestrone concentrations: an observational study of  young to middle-aged women.  J Steroid Biochem Mol Biol  86:71-7.
  44. Alvarez-Vasquez RB, Axelrod D, Frenkel K, Newman MC, Sepkovic DW, Bradlow HL, Zumoff B. (2003). Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer.   Horm Metab Res  35:58-61.
  45. Lotinun S, Westerlind KC, Kennedy AM, Turner RT. (2003).  Comparative effects of long-term continuous release of 16alpha-hydroxyestrone and 17beta-estradiol on bone, uterus, and serum cholesterol in ovariectomized adult rats.  Bone 33:124-31.
  46. Jernstrom H, Klug TL, Sepkovic DW, Bradlow HL, Narod SA. (2003) Predictors of the plasma ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups.  Carcinogenesis 24:991-1005.
  47. Thompson DS, Kirshner MA, Klug TL, Kastango KB, Pollock BG.  (2003).  A Preliminary Study of the Effect of Fluoxetine Treatment on the 2:16-alpha-Hydroxyestrone Ratio in Young Women. Ther Drug Monit  25:125-128.
  48. Fowke JH, Qi D, Bradlow HL, Shu XO, Gao YT, Cheng JR, Jin F, Zheng W.  (2003).  Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection. Steroids 68: 65-72.
  49. Muti P, Westerlind K, Wu T, Grimaldi T, De Berry III J, Schunemann H, Freudenheim JL, Hill H, Carruba G, Bradlow H.  (2002). Urinary estrogen metabolites and prostate cancer: a case-control study in the United States.  Cancer Causes Control 13: 947-955.
  50. Williams AE, Maskarinec G, Franke AA, Stanczyk FZ. (2002). The temporal reliability of serum estrogens, progesterone, gonadotropins, SHBG and urinary estrogen and progesterone metabolites in premenopausal women.  BMC Womens Health 2:13-
  51. Kasim-Karakas SE, Almario RU, Gregory L, Todd H, Wong R, Lasley BL.  (2002).  Effects of prune consumption on the ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone.   Am J Clin Nutr 76:1422-1427.
  52. Bradlow, H.L. and Sepkovic D.W. (2002).  Diet and Breast Cancer. Ann. N.Y. Acad. Sci  963: 247-267. Review.
  53. Mueck AO, Seeger H, Wallwiener D.  (2002).  Impact of hormone replacement therapy on endogenous estradiol  metabolism in postmenopausal women. Maturitas 3: 87-93.
  54. Lord RS, Bongiovanni B, Bralley JA. (2002). Estrogen metabolism and the diet-cancer connection: rationale for assessing the ratio of urinary hydroxylated estrogen metabolites.  Altern Med Rev 7:112-29. Review.
  55. Ursin G, London S, Yang D, Tseng CC, Pike MC, Bernstein L, Stanczyk FZ,Gentzschein E. (2002)  Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women. Breast Cancer Res Treat 72:139-43.
  56. Mueck AO, Seeger H, Graser T, Oettel M, Lippert TH. (2002) The effects of postmenopausal hormone replacement therapy and oral contraceptives on the endogenous estradiol metabolism.  Horm Metab Res. 33:744- 747.
  57. Villareal RC, Leelawattanna R, Klug T, Civitelli R. (2001)  HRT/ERT alters estrogen catabolism and catabolic products may predict response to therapy.   J Bone Miner Res  16: S538.
  58. McAlindon TE, Gulin J, Chen T, Klug T, Lahita R, Nuite M.  (2001). Indole-3-carbinol in women with SLE: effect on estrogen metabolism and disease activity. Lupus 10:779-83.
  59. Yoo HJ, Sepkovic DW, Bradlow HL, Yu GP, Sirilian HV, Schantz SP.  (2001). Estrogen metabolism as a risk factor for head and neck cancer.  Otolaryngol Head Neck Surg. 124:241-247.
  60. Riza E, dos Santos Silva I, De Stavola B, Bradlow HL, Sepkovic DW, Linos D,  Linos A. (2001). Urinary estrogen metabolites and mammographic parenchymal patterns in postmenopausal women.  Cancer Epidemiol Biomarkers Prev 10:627-34.
  61. Ursin G, Wilson M, Henderson BE, Kolonel LN, Monroe K, Lee HP, Seow A, Yu MC, Stanczyk FZ, Gentzschein E. (2001).  Do Urinary Estrogen Metabolites Reflect the Differences in Breast Cancer Risk between Singapore Chinese and United States African-American and White Women? Cancer Res 61:3326-3329.
  62. Fowke JH, Longcope C, Hebert JR (2001). Macronutrient intake and estrogen metabolism in healthy postmenopausal women. Breast Cancer Res Treat 65:1-10.
  63. Kishida T, Beppu M, Nashiki K, Izumi T, Ebihara K. (2000). Effect of dietary soy isoflavone aglycones on the  urinary 16alpha-to-2-hydroxyestrone ratio in C3H/HeJ mice. Nutr Cancer 38:209-214.
  64. Kuller LH, Matthews KA, Meilhan EN. (2000).  Estrogens and women's health: Interrelation of coronary heart disease, breast cancer, and osteoporosis.  J Steroid Biochem Mol Biol 74:297-309.
  65. Leelawattana R, Ziambaras K, Roodman-Weiss J, Lyss C, Wagner D, Klug T, Civitelli R. (2000).  The oxidative metabolism of estradiol conditions post-menopausal bone density and bone loss.  J Bone Miner Res 15:2513-2520.
  66. Seeger H, Mueck AO, Lippert TH. (2000).  Effect of norethisterone acetate on estrogen metabolism in postmenopausal women. Horm Metab Res 32:436-439.
  67. Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F. (2000).  Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women.  Epidemiology 11:635-640.
  68. Fowke JH, Longcope C, Hebert JR. (2000). Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women.  Cancer Epidemiol Biomarkers Prev  9:773-779.
  69. Bell MC, Crowley-Nowick P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, Mayeaux EJ, Tucker A, Turbat-Herrera EA, Mathis JM. (2000).  Placebo-Controlled Trial of Indole-3-Carbinol in the Treatment of CIN.  Gynecol Oncol 78:123-129.
  70. Haggans CJ, Travelli EJ, Thomas W, Martini MC, Slavin JL. (2000).  The effect of flaxseed and wheat bran consumption on urinary estrogen metabolites in premenopausal women.  Cancer Epidemiol Biomarkers Prev 9:719-725.
  71. Dupont E, Klug T, McCann C, Vincent D, Shons A, Teng S, Reintgen D, Cantor A, Cox C. (2000).  The prognostic value of altered estrogen metabolism in breast cancer..  Abstract 53rd Annual Cancer Symposium, Society of Surgical Oncology, March 16-19, New Orleans, LA, USA.  Ann Surg Oncol 7(1): Suppl.
  72. Lu LJ, Cree M, Josyula S, Nagamani M, Grady JJ, Anderson KE. (2000).  Increased urinary excretion of 2-hydroxyestrone but not 16alpha-hydroxyestrone in premenopausal women during a soya diet containing isoflavones. Cancer Res 60: 1299-1305.
  73. Falk RT, Rossi SC, Fears TR, Sepkovic DW, Migella A, Adlercreutz H, Donaldson J, Bradlow HL, Ziegler RC. (2000).  A new ELISA kit for measuring 2-hydroxyestrone and 16a-hydroxyestrone and their ratio: reproducibility, validity, and assay performance after freeze-thaw cycling and preservation by boric acid.  Cancer Epidemiol Biomarkers Prev 9:81-87.
  74. Michaud DS, Manson JE, Spieglman, Barbieri RL, Sepkovic DW, Bradlow HL, Hankinson SE. (1999).  Reproducibility of plasma and urinary sex hormone levels in premenopausal women over a one-year period.  Cancer Epidemiol Biomarkers Prev 8:1059-1064.
  75. Martini MC, Dancisak BB, Haggans CJ, Thomas W, Slavin JL. (1999).  Effects of soy intake on sex hormone metabolism in premenopausal women.  Nutr Cancer 34:133-139.
  76. Chen Z, Zheng W, Dunning LM, Anderson KG, Parrish RS, Holtzman JL. (1999).  Within-person variability of the ratios of urinary 2-hydroxyestrone to 16alpha-hydroxyestrone in Caucasian women.  Steroids 64:856-859.
  77. Haggans CJ, Hutchins AM, Olson BA, Thomas W, Martini MC, Slavin JL. (1999).  Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women.  Nutr Cancer 33:188-195.
  78. Taioli E, Bradlow HL, Garbers SV, Sepkovic DW, Osborne MP, Trachman J, Ganguly S, Garte SJ. (1999).  Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk.  Cancer Detect Prev 23:232-237.
  79. Cree M, Josyula S, Anderson KE, Nagamani M, and Lu, L-JW. (1999).  Altered urinary excretion of 2-OH-estrone to 16-OH-estrone in women after soya isoflavone  consumption.  Proc Amer Assoc Cancer Res 40:302 Abstract 2007.
  80. Westerlind KC, Gibson KJ, Wolfe P. (1999).  The effect of diurnal and menstrual cyclicity and menopausal status on estrogen metabolites:implications for disease-risk assessment.  Steroids 64:233-243.
  81. Ursin G, London S, Stanczyk FZ, Gentzschein E, Paganini-Hill A, Ross RK, Pike MC. (1999).  Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women.  J Natl Cancer Inst 91:1067-1072.
  82. Bradlow HL, Kabat GC. (1998).  Re: “A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer". Environ Health Perspectives 106: A126-127.
  83. Auborn K, Abramson A, Bradlow HL, Sepkovic D, Mullooly V. (1998).  Estrogen metabolism and laryngeal papillomatosis: a pilot study.  Anticancer Res 18: 4569-4573.
  84. Lippert TH, Seeger H, Mueck AO. (1998).  Estradiol metabolism during oral and transdermal estradiol replacement therapy in postmenopausal women.  Horm Metab Res 30:598-600.
  85. Meilahn EN, De Stavola B, Allen DS, Fentiman, I, Bradlow HL, Sepkovic DW, Kuller LH. (1998).  Do urinary estrogen metabolites predict breast cancer ?  Follow up of the Guernsey III cohort.  Br J Cancer 78:1250-1255.
  86. Bradlow HL, Sepkovic DW, Klug T, Osborne MP. (1998).  Application of an improved ELISA assay to the analysis of urinary estrogen metabolites.  Steroids 63:406-413.
  87. Ho GH, Luo XW, Ji CY, Foo SC, Ng GH.  (1998).  Using 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk.  Ann Acad Med Singapore 27: 294-299.
  88. Rosen CA, Woodson GE, Thompson JW, Hengesteg AP, Bradlow HL. (1998).  Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis.  Otolaryngol Head Neck 118: 810-815.
  89. Bello SM, Gentzschein E, Shoupe D, Stanczyk FZ.  (1998).  Effect of transdermal estradiol on the balance between urinary 2- and 16a-hydroxyestrone in postmenopausal women., The 80th Annual meeting of the Endocrine Society, June 24-27, 1998,  New Orleans, Louisiana, Abstract P3-56.
  90. Westerlind K, Gibson KJ, Malone P, Evans GL, Turner RT. (1998).  Differential effects of estrogen metabolites on bone and reproductive tissues of ovarectomized rats  J Bone Miner Res  13: 1021-1031.
  91. Zheng W, Dunning L, Jin F, Holtzman J. (1998).  Correspondence re: Kabat et al., Urinary estrogen metabolites and breast cancer: a case-control study in  Cancer Epidemiol Biomarkers Prev, 6: 505-509, 1997.  Cancer Epidemiol Biomarkers Prev 7: 85-86
  92. Holloway L, Marcus R, Klug T. (1998).  Effects of  hormone replacement on circulating estrogens and estrogen metabolite ratios in postmenopausal women: relationship to BMD response.  Bone 23:S506.
  93. Lemon HM, Rodriquez-Sierra JF. (1997).  Correspondence  re: differences in estrogen metabolism in healthy women.  J Natl Cancer Inst  89: 1626-1627.
  94. Wong GY, Bradlow HL, Sepkovic D, Mehl S, Mailman J, Osborne MP. (1997).  Dose-ranging study of indole-3-carbinol for breast cancer prevention.  J Cell Biochem  [Suppl 28-29: 111-116].
  95. Leelawattana R, Ziambara K, Lyss C, Roodman-Weiss J, Wagner D, Klug T, Civitelli R. (1997). Estrogen metabolites in urine of early postmenopausal women correlate with bone density. J Bone Miner Res 12 [Suppl 1] .
  96. Kabat GC, Chang CJ, Sparano JA, Sepkovic DW, Hu XP, Khalil A, Rosenblatt R, Bradlow HL. (1997).  Urinary estrogen metabolites and breast cancer: a case-control study.  Cancer Epidemiol Biomarkers Prev 6: 505-509.
  97. Ziegler RG, Rossi SC, Fears TR, Bradlow HL, Adlercreutz H, Sepkovic DW, Kiriu P, Whala K, Vaught JB, Donaldson JL, Gail MH, Siiteri PK, Hoover RN. (1997).  Quantifying  estrogen metabolism: An evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16a-hydroxyestrone in urine.  Environ Health Perspect 105: (Suppl. 3) 607-614. 
  98. Ursin G, London S, Stanczyk FZ, Gentzschein E, Paganini-Hill A, Ross RK, Pike MC. (1997).  A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer. Environ Health Perspect 105: (Suppl. 3) 601-605.
  99. Kall MA, Vang O, Clausen J. (1997).  Effects of dietary broccoli on human drug metabolising activity. Cancer Lett 114: 169-170.
  100. Coker AL, Crane MM, Sticca RP, Sepkovic DW. (1997).  Correspondence, Re: Ethnic differences in estrogen metabolism in healthy women.  J Natl Cancer Inst  89: 89.
  101. Westerlind KC, Gibson KG, Wolfe P. (1997).  Diurnal and menstrual cycles of 2- and 16a-hydroxyestrones in reproductive-age women.  Proceedings Endocrine Society 138:259.
  102. Westerlind KC, Gibson KJ, Malone P, Evans GL, Turner RT. (1997).  16a-hydroxyestrone is a naturally produced tissue-selective estrogen agonist  Proceedings Endocrine Society 138:548.
  103. Bradlow HL, Sepkovic DW, Telang NT, Osborne MP. (1996).  Indole-3-Carbinol: A novel approach to breast cancer prevention (see Figure 22 in text).  Ann N Y Acad Sci 768:180-200.
  104. Taioli E, Trachtman J, Chen X, Sepkovic DW, Bradlow HL, Toniolo P. (1996)  Correlation of estradiol 2-hydroxylation and breast cancer risk in patients carrying the MSP-1 polymorphism of CyP4501A1.  Proc Annu Meet Am Assoc Cancer Res 37: Abstract 1697.
  105. Taioli E, Garte SJ, Trachman J, Garbers S, Sepkovic DW, Osborne MP, Mehl S, Bradlow  HL. (1996).  Ethnic differences in estrogen metabolism in healthy women.  J Natl Cancer Inst  88: 617.
  106. Crane MM, Sepkovic D, Robertson NR, Lopez, A, Blackhurst DW, Sticca RP, Coker AL, Fishman J, Bradlow HL. (1996).  Association of estrogen urinary metabolites and breast cancer: pilot study.  Breast Cancer Res Treat  37:68.
  107. Kall MA, Vang O, Clausen J. (1996).  Effects of dietary broccoli on human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone, and chlorzoxazone metabolism.  Carcinogenesis 17: 793-799.
  108. Pasagian-McCauley A, Meilahn EN, Bradlow HL, Sepkovic DW, Buhara AM, Simkin-Silverman L, Wing RR, Kuller LH. (1996).  Urinary markers of estrogen metabolism: 2- and 16a-hydroxylation in premenopausal women. Steroids 61: 461-467.
  109. Fleisher M, Sepkovic D, Bradlow HL, Schwartz MK. (1996).  Estrogen metabolite ratios as biomarkers of hormonally related breast cancer risk.  Clin Chem 42: A689, S261.
  110. Chen C, Malone KE, Prunty J, Daling JR. (1996).  Measurement of urinary estrogen metabolites using a monoclonal enzyme-linked immunoassay kit: assay performance and feasibility for epidemiological studies.   Cancer Epidemiol Biomarkers Prev 5:727-732.
  111. Luo XW, Ng EH, Foo SC, Jeyaratnam J. (1995).  The ratio of urinary 2-hydroxyestrone and 16 alpha-hydroxyestrone (2/16(OHE1): a potential risk marker for breast cancer. 12th Asian Pacific Cancer Conference , Singapore, October 17-20,  Abstract,  p. 62.
  112. Sepkovic DW, Bradlow HL, Ho G, Hankinson S, Gong L, Osborne MP, Fishman J. (1995).  Estrogen metabolite ratios and risk assessment of hormone related cancers: Assay validation and prediction of cervical cancer risk.    Ann NY Acad Sci  768:312-316
  113. Hodge J, Roodman-Weiss J, Lyss C, Wagner D, Klug T, Civitelli R. (1995).  Increased inactive estrogen metabolites in urine of early postmenopausal women with low bone density.  J Bone Miner Res 10 [Suppl 1] :S444.
  114. Klug TL, Bradlow HL, Sepkovic DW. (1994).  Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16a-hydroxyestrone in urine. Steroids 59: 648-655.
Publications

2007. Immuna Care Corporation.